Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Integrated genomic analyses of ovarian carcinoma.

Cancer Genome Atlas Research Network.

Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166. Erratum in: Nature. 2012 Oct 11;490(7419):298.

2.

Diverse somatic mutation patterns and pathway alterations in human cancers.

Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, Seshagiri S.

Nature. 2010 Aug 12;466(7308):869-73. doi: 10.1038/nature09208. Epub 2010 Jul 28.

PMID:
20668451
3.

A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress.

Peterson D, Lee J, Lei XC, Forrest WF, Davis DP, Jackson PK, Belmont LD.

Cancer Res. 2010 Aug 1;70(15):6325-35. doi: 10.1158/0008-5472.CAN-10-0015. Epub 2010 Jul 20.

4.

Cancer statistics, 2010.

Jemal A, Siegel R, Xu J, Ward E.

CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.

5.

Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer.

Lin B, White JT, Wu J, Lele S, Old LJ, Hood L, Odunsi K.

Proteomics Clin Appl. 2009 Jul 1;3(7):853-861.

6.

Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.

Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K.

Cancer. 2010 Jun 1;116(11):2621-34. doi: 10.1002/cncr.24987.

7.

Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.

Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R.

Neoplasia. 2010 Feb;12(2):161-72.

8.
9.

Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome.

Gabeau-Lacet D, Engler D, Gupta S, Scangas GA, Betensky RA, Barker FG 2nd, Loeffler JS, Louis DN, Mohapatra G.

J Neuropathol Exp Neurol. 2009 Oct;68(10):1155-65. doi: 10.1097/NEN.0b013e3181ba3952.

10.

Ovarian cancer pathogenesis: a model in evolution.

Karst AM, Drapkin R.

J Oncol. 2010;2010:932371. doi: 10.1155/2010/932371. Epub 2009 Sep 6.

11.

Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.

Gorringe KL, Ramakrishna M, Williams LH, Sridhar A, Boyle SE, Bearfoot JL, Li J, Anglesio MS, Campbell IG.

Genes Chromosomes Cancer. 2009 Oct;48(10):931-42. doi: 10.1002/gcc.20694.

PMID:
19603523
12.

Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.

Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S, Nephew KP.

BMC Med Genomics. 2009 Jun 8;2:34. doi: 10.1186/1755-8794-2-34.

13.

Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.

Yoshihara K, Tajima A, Komata D, Yamamoto T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, Fujiwara H, Kudo Y, Inoue I, Tanaka K.

Cancer Sci. 2009 Aug;100(8):1421-8. doi: 10.1111/j.1349-7006.2009.01204.x. Epub 2009 May 26.

14.

CGHregions: dimension reduction for array CGH data with minimal information loss.

van de Wiel MA, Wieringen WN.

Cancer Inform. 2007 Feb 8;3:55-63.

15.

High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors.

Haverty PM, Hon LS, Kaminker JS, Chant J, Zhang Z.

BMC Med Genomics. 2009 May 6;2:21. doi: 10.1186/1755-8794-2-21.

16.

Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.

Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, Wang Y, Kurman RJ, Shih IeM, Wang TL.

Cancer Res. 2009 May 1;69(9):4036-42. doi: 10.1158/0008-5472.CAN-08-3913. Epub 2009 Apr 21. Erratum in: Cancer Res. 2009 Jun 15;69(12):5267.

17.

Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.

Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, Lancaster JM.

Clin Cancer Res. 2009 Apr 1;15(7):2448-55. doi: 10.1158/1078-0432.CCR-08-2430. Epub 2009 Mar 24.

18.

Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.

Farley J, Fuchiuji S, Darcy KM, Tian C, Hoskins WJ, McGuire WP, Hanjani P, Warshal D, Greer BE, Belinson J, Birrer MJ.

Gynecol Oncol. 2009 Jun;113(3):341-7. doi: 10.1016/j.ygyno.2009.02.009. Epub 2009 Mar 9.

PMID:
19272639
19.

Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.

Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, Chiew YE, Traficante N, Fereday S, Johnson D, Fox S, Sellers W, Urashima M, Salvesen HB, Meyerson M, Bowtell D; AOCS Study Group.

Clin Cancer Res. 2009 Feb 15;15(4):1417-27. doi: 10.1158/1078-0432.CCR-08-1564. Epub 2009 Feb 3.

20.

Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer.

Straehle C, Cardoso F, Azambuja E, Dolci S, Meirsman L, Vantongelen K, Ignatiadis M, Sotiriou C, Piccart-Gebhart MJ.

Crit Care Med. 2009 Jan;37(1 Suppl):S22-9. doi: 10.1097/CCM.0b013e3181921598.

PMID:
19104222
Items per page

Supplemental Content

Write to the Help Desk